Vigil Neuroscience reports Interim Data from Phase 2 Clinical Trial
Vigil Neuroscience presented their findings from 6 patients during the first 6 months of the Phase 2 Ignite proof-of-concept clinical trial. The data is promising, […]
Learn More
Potential use of glucocorticosteroids (GCs) in CSF1R mutation carriers
The thoughts presented below by Drs. Dulski, Stanley, Chitu and Wszolek have significant limitations and must be read only as their personal views, and not […]
Learn More
Genetic Testing Survey
Survey about genetic testing Vigil Neuroscience, a biotechnology company researching potential treatments for ALSP, is engaging with the ALSP patient community, caregivers, advocacy groups, and […]
Learn More